Received Sep 16, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| COVID19 | COVID19 (COVID19 (PFIZER-BIONTECH)) | PFIZER\BIONTECH | 1 | NA0587 | — |
Significant swelling, hardness and redness of upper right arm, deltoid region.; Bruising at injection site appeared later.; Significant swelling, hardness and redness of upper right arm, deltoid region.; Significant swelling, hardness and redness of upper right arm, deltoid region.; Right shoulder pain; This is a spontaneous report received from a Nurse. A 79-year-old female patient received BNT162b2 omicron (lp.8.1) (COMIRNATY (2025-2026 FORMULA)), on 05Sep2025 as dose 1, single (Lot number: NA0587) at the age of 79 years for covid-19 immunisation. The patient's relevant medical history was not reported. Concomitant medication(s) included: VITAMIN D NOS; CALCIUM. Past drug history included: Contrast dye, reaction(s): "Allergy". The following information was reported: VACCINATION SITE BRUISING (non-serious) with onset 05Sep2025, outcome "recovering", described as "Bruising at injection site appeared later."; ARTHRALGIA (non-serious) with onset 05Sep2025, outcome "recovering", described as "Right shoulder pain"; VACCINATION SITE INDURATION (non-serious), VACCINATION SITE SWELLING (non-serious), VACCINATION SITE ERYTHEMA (non-serious) all with onset 05Sep2025, outcome "recovering" and all described as "Significant swelling, hardness and redness of upper right arm, deltoid region.". Therapeutic measures were not taken as a result of vaccination site induration, vaccination site bruising, vaccination site erythema, arthralgia. No follow-up attempts are possible.
VITAMIN D NOS; CALCIUM